Gilead Sciences (GILD -2.2%) slips despite saying that topline results from two Phase 3 studies...


Gilead Sciences (GILD -2.2%) slips despite saying that topline results from two Phase 3 studies of its nucleotide sofosbuvir met its endopoint among patients with chronic hepatitis C virus infection. Morgan Stanley reiterates its Overweight on the news, saying that additional Phase III data for sofosbuvir supports a "best in class" profile and a multi-billion dollar opportunity for GILD.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs